Allogene Therapeutics, Inc.
NASDAQ:ALLO
1.11 (USD) • At close May 21, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | 2019 Q4 | 2019 Q3 | 2019 Q2 | 2019 Q1 | 2018 Q4 | 2018 Q3 | 2018 Q2 | 2018 Q1 | 2017 Q4 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 0 | -0.022 | 0 | 0 | 0.022 | -0.044 | 0.022 | 0.022 | 0.03 | 0.047 | 0.049 | 0.086 | 0.061 | 0.051 | 0.049 | 0.044 | 38.345 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 0 | -0.022 | 0 | 0 | 0.022 | -0.044 | 0.022 | 0.022 | 0.03 | 0.047 | 0.049 | 0.086 | 0.061 | 0.051 | 0.049 | 0.044 | 38.345 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 50.2 | 44.972 | 44.713 | 50.355 | 52.259 | 54.661 | 45.977 | 62.038 | 80.238 | 75.419 | 63.641 | 57.171 | 60.156 | 53.983 | 58.72 | 52.29 | 55.183 | 52.228 | 51.421 | 47.296 | 42.042 | 49.363 | 39.995 | 31.774 | 23.403 | 18.504 | 10.87 | 122.486 | 0 | 0 |
| General & Administrative Expenses
| 14.991 | 15.518 | 16.333 | 16.087 | 17.267 | 17.224 | 17.041 | 18.524 | 18.884 | 21.002 | 18.897 | 19.509 | 19.897 | 19.961 | 18.999 | 18.783 | 16.363 | 17.134 | 16.619 | 15.862 | 15.641 | 15.212 | 15.016 | 14.187 | 13.058 | 14.542 | 11.317 | 12.526 | 2.597 | 0 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 14.991 | 15.518 | 16.333 | 16.087 | 17.267 | 17.224 | 17.041 | 18.524 | 18.884 | 21.002 | 18.897 | 19.509 | 19.897 | 19.961 | 18.999 | 18.783 | 16.363 | 17.134 | 16.619 | 15.862 | 15.641 | 15.212 | 15.016 | 14.187 | 13.058 | 14.542 | 11.317 | 12.526 | 2.597 | 0.002 |
| Other Expenses
| 0 | 0 | 10.728 | 4.989 | 0 | 13.245 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 65.191 | 60.49 | 71.774 | 71.431 | 69.526 | 85.13 | 63.018 | 80.562 | 99.122 | 96.421 | 82.538 | 76.68 | 80.053 | 73.944 | 77.719 | 71.073 | 71.546 | 69.362 | 68.04 | 63.158 | 57.683 | 64.575 | 55.011 | 45.961 | 36.461 | 33.046 | 22.187 | 135.012 | 2.597 | 0.002 |
| Operating Income
| -65.191 | -60.49 | -71.774 | -71.431 | -69.504 | -85.174 | -62.996 | -80.54 | -99.092 | -96.374 | -82.489 | -76.594 | -79.992 | -73.893 | -77.67 | -71.029 | -33.201 | -69.362 | -68.04 | -63.158 | -57.683 | -64.575 | -55.011 | -45.961 | -36.461 | -33.046 | -22.187 | -135.012 | -2.597 | -0.002 |
| Operating Income Ratio
| 0 | 0 | 0 | 0 | -3,159.273 | 1,935.773 | -2,863.455 | -3,660.909 | -3,303.067 | -2,050.511 | -1,683.449 | -890.628 | -1,311.344 | -1,448.882 | -1,585.102 | -1,614.295 | -0.866 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 5.458 | 0.994 | 5.481 | 5.073 | 4.504 | -4.083 | 0.709 | 1.308 | -0.876 | 1.527 | -0.659 | 1.807 | 0.142 | -0.975 | -0.516 | 0.093 | 0.186 | 0.792 | 1.843 | 2.184 | 3.203 | 3.39 | 4.309 | 4.559 | 4.825 | 2.42 | -21.31 | 0.11 | 0 | 0 |
| Income Before Tax
| -59.733 | -59.496 | -66.293 | -66.358 | -65 | -89.257 | -62.287 | -79.232 | -99.968 | -94.847 | -83.148 | -74.787 | -79.85 | -74.868 | -78.186 | -70.936 | -33.015 | -68.57 | -66.197 | -60.974 | -54.48 | -61.185 | -50.702 | -41.402 | -31.636 | -30.626 | -43.497 | -134.902 | -2.597 | -0.002 |
| Income Before Tax Ratio
| 0 | 0 | 0 | 0 | -2,954.545 | 2,028.568 | -2,831.227 | -3,601.455 | -3,332.267 | -2,018.021 | -1,696.898 | -869.616 | -1,309.016 | -1,468 | -1,595.633 | -1,612.182 | -0.861 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0.443 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0.155 | 0.033 | -0.159 | -0.05 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -59.733 | -59.939 | -66.293 | -66.358 | -65 | -89.257 | -62.287 | -79.232 | -99.968 | -94.847 | -83.148 | -74.787 | -79.85 | -74.868 | -78.186 | -70.936 | -33.015 | -68.57 | -66.197 | -60.974 | -54.48 | -61.03 | -50.735 | -41.243 | -31.586 | -30.509 | -43.497 | -134.902 | -2.597 | -0.002 |
| Net Income Ratio
| 0 | 0 | 0 | 0 | -2,954.545 | 2,028.568 | -2,831.227 | -3,601.455 | -3,332.267 | -2,018.021 | -1,696.898 | -869.616 | -1,309.016 | -1,468 | -1,595.633 | -1,612.182 | -0.861 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.28 | -0.28 | -0.32 | -0.35 | -0.38 | -0.51 | -0.37 | -0.54 | -0.68 | -0.66 | -0.58 | -0.52 | -0.56 | -0.54 | -0.57 | -0.53 | -0.25 | -0.53 | -0.52 | -0.53 | -0.5 | -0.58 | -0.5 | -0.41 | -0.32 | -0.37 | -0.38 | -1.19 | -0.059 | 0 |
| EPS Diluted
| -0.28 | -0.28 | -0.32 | -0.35 | -0.38 | -0.51 | -0.37 | -0.54 | -0.68 | -0.66 | -0.58 | -0.52 | -0.56 | -0.54 | -0.57 | -0.53 | -0.25 | -0.53 | -0.52 | -0.53 | -0.5 | -0.58 | -0.5 | -0.41 | -0.32 | -0.37 | -0.38 | -1.19 | -0.059 | 0 |
| EBITDA
| -56.484 | -56.182 | -62.986 | -62.798 | -65.949 | -68.452 | -58.715 | -76.897 | -95.585 | -93.306 | -78.629 | -72.919 | -76.3 | -69.651 | -75.34 | -69.065 | -31.283 | -59.496 | -66.23 | -61.27 | -55.639 | -59.33 | -53.683 | -44.812 | -35.766 | -30.079 | -39.636 | -134.562 | -2.597 | -0.002 |
| EBITDA Ratio
| 0 | 0 | 0 | 0 | -2,997.682 | 1,555.727 | -2,668.864 | -3,495.318 | -3,186.167 | -1,985.234 | -1,604.673 | -847.895 | -1,250.82 | -1,365.706 | -1,537.551 | -1,569.659 | -0.816 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |